MX2019009619A - Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo. - Google Patents

Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.

Info

Publication number
MX2019009619A
MX2019009619A MX2019009619A MX2019009619A MX2019009619A MX 2019009619 A MX2019009619 A MX 2019009619A MX 2019009619 A MX2019009619 A MX 2019009619A MX 2019009619 A MX2019009619 A MX 2019009619A MX 2019009619 A MX2019009619 A MX 2019009619A
Authority
MX
Mexico
Prior art keywords
irtca
cancer
ifn
antibody
inducible regulatory
Prior art date
Application number
MX2019009619A
Other languages
English (en)
Inventor
S Kwon Byoung
Joo LEE Seoung-
Won Lee Joong
Lee Seunghyun
Original Assignee
Eutilex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd
Publication of MX2019009619A publication Critical patent/MX2019009619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan anticuerpos Anti-Cáncer Convertibles de Célula T Regulatoria Inducibles por IFN-? (IRTCA) y fragmentos de unión al antígeno de los mismos que se unen a un polipéptido de TNFR inducible por activación (AITR); también se proporcionan varios métodos in vitro e in vivo y composiciones relacionadas a los anticuerpos IRTCA descritos en la presente; métodos incluyen, por ejemplo, cambiar la secreción de citosina de las células T in vivo o in vitro y la prevención y/o tratamiento terapéutico de cáncer utilizando un anticuerpo IRTCA o fragmento del mismo.
MX2019009619A 2017-02-10 2018-02-09 Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo. MX2019009619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457422P 2017-02-10 2017-02-10
PCT/IB2018/000201 WO2018146549A1 (en) 2017-02-10 2018-02-09 IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2019009619A true MX2019009619A (es) 2019-12-18

Family

ID=63108020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009619A MX2019009619A (es) 2017-02-10 2018-02-09 Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.

Country Status (11)

Country Link
US (3) US10919976B2 (es)
EP (2) EP3472209A4 (es)
JP (1) JP2020508636A (es)
KR (1) KR20190117467A (es)
CN (1) CN109689691A (es)
AU (1) AU2018218324A1 (es)
BR (1) BR112019016513A2 (es)
CA (1) CA3052740A1 (es)
MX (1) MX2019009619A (es)
SG (2) SG10201914115RA (es)
WO (1) WO2018146549A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
MX2019009619A (es) 2017-02-10 2019-12-18 Eutilex Co Ltd Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3321157A1 (de) 1983-06-11 1984-12-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1h-pyrrol-2,5-dionen
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
DE69840723D1 (de) 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
SG178991A1 (en) * 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
KR102433464B1 (ko) * 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
CN106459203B (zh) * 2014-06-06 2021-08-03 百时美施贵宝公司 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2019009619A (es) * 2017-02-10 2019-12-18 Eutilex Co Ltd Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.

Also Published As

Publication number Publication date
US20190233535A1 (en) 2019-08-01
EP3472209A1 (en) 2019-04-24
JP2020508636A (ja) 2020-03-26
US10626183B2 (en) 2020-04-21
EP3882271A2 (en) 2021-09-22
SG11201907242TA (en) 2019-09-27
EP3472209A4 (en) 2020-07-29
WO2018146549A1 (en) 2018-08-16
BR112019016513A2 (pt) 2020-04-07
KR20190117467A (ko) 2019-10-16
US20190330358A1 (en) 2019-10-31
US20210277139A1 (en) 2021-09-09
US10919976B2 (en) 2021-02-16
SG10201914115RA (en) 2020-02-27
AU2018218324A1 (en) 2019-08-22
EP3882271A3 (en) 2022-01-05
CN109689691A (zh) 2019-04-26
CA3052740A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX369148B (es) Agentes de unión kir3dl2.
PE20121649A1 (es) Anticuerpos monoclonales frente a progastrina y sus usos
MY200162A (en) Anti-gitr antibodies and uses thereof
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2020013017A (es) Materiales y metodos para tratar cancer.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2021004993A (es) Materiales y metodos para tratar cancer.
MX2019009619A (es) Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
MX2023014836A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
MX2021002077A (es) Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer.